Slide 1: When Your Path Is Unclear, We Point the Way
© 2025 CLEARPOINT NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT May 2025
Slide 2: Disclaimer
DISCLAIMER This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the f
Slide 3: Our Company
OUR COMPANY We Enable Cell, Gene and Device Therapies by Offering Precise Navigation to the Brain and Spine Our Unique Platform Includes Both Proven Clinical Products Used by Neurosurgeons, and Drug Development Services Used by BioPharma Partners © 2025 CLEARPOINT NEURO
Slide 4: ClearPoint Neuro Executive Summary
CLEARPOINT NEURO EXECUTIVE SUMMARY 15+ years building a complete drug delivery ecosystem including navigation solutions, predictive modeling, delivery devices, infusion monitoring software and clinical case support Combination device success, proprietary technology and deep FDA experience provide ou
Slide 5: Neurological diseases cost Americans nearly $800 Billion annually
Neurological diseases cost Americans nearly $800 Billion annually. The only way to decrease these costs is to improve treatment. Despite some available treatments, very few of these patients undergo a direct surgical intervention to improve their quality of life… © 2025 CLEARPOINT NEURO More than 30
Slide 6: Our Goal: Addressing Two Primary Barriers to Treatment
We will Enable fast, minimally-invasive, asleep procedures for a more comfortable and predictable patient experience… © 2025 CLEARPOINT NEURO We will partner to Develop Device, Cell and Gene Therapies that may cure the underlying disease and restore function… Our Goal is to Help More Patients by Add
Slide 7: Partners have programs selected for expedited review
© 2025 CLEARPOINT NEURO Partners have programs selected for expedited review - the FDA recognizes the urgency The Future of Cell and Gene Therapy is Not Coming… It is HERE TODAY Our Company 7 Partner has received FDA approval for a neuro gene therapy that is co-labeled with ClearPoint 1
Slide 8: Active Clinical-Stage Partners Selected for Expedited Review
7 Active Clinical-Stage Partners have been selected for expedited review including: AADC Deficiency Huntington's’ Disease Parkinson’s Disease Epilepsy (MTLE) Parkinson’s Disease Parkinson’s Disease Frontotemporal Dementia RMAT - June 2024 May 2024 February 2025 June 2024 - - Indication Fast Track De
Slide 9: In 2025 Our Journey Enters the Next Chapter
In 2025 Our Journey Enters the NEXT CHAPTER Our Company © 2025 CLEARPOINT NEURO Discovery. Design. Neurosurgeon Led Ideation Unique MRI Navigation Initial FDA Clearance and Product Revenue Accumulation of Clinical Trial Experience Using SmartFlow® Maestro A.I. Software Development Initial IP Generat
Slide 10: Our Start: Unique Neurosurgery Navigation Guided by Live MRI
Our Start: Unique Neurosurgery Navigation Guided by Live MRI Discovery. Design. © 2025 CLEARPOINT NEURO Neurosurgery has traditionally been done via open craniotomy or by using CT guidance in the operating room The historical limitations of CT accuracy would often require patients to remain awake fo
Slide 11: Our Start: Decide, Guide & Confirm
Our Start: Decide, Guide & Confirm Discovery. Design. © 2025 CLEARPOINT NEURO Three Primary Use Cases demonstrated the value of the ClearPoint MRI Navigation System: Functional Neurosurgeons could confidently place DBS electrodes with the patient comfortably asleep Neuro-Oncologists could perform en
Slide 12: Our Start: Assemble the Building Blocks
Our Start: Assemble the Building Blocks Discovery. Design. © 2025 CLEARPOINT NEURO Leveraging our unique platform and dedicated team, we developed and acquired essential technologies necessary to complete the entire ecosystem for MRI Guided Navigation, and with a focus on cell and gene therapy deliv
Slide 13: Building the Business
Building the Business Funded. Foundation. © 2025 CLEARPOINT NEURO ClearPoint Neuro Navigation Software v.2.2.1 ClearPoint Array Software v.1.2 ClearPoint Maestro Brain Model SmartFrame XG Kit Components SmartFrame OR with ClearPointer Inflexion Head Fixation Frame SmartFrame Array Kit Components Cle
Slide 14: Our Four-Pillar Growth Strategy Remains Our Foundation
Building the Business: Our Four-Pillar Growth Strategy Remains Our Foundation Funded. Foundation. © 2025 CLEARPOINT NEURO BIOLOGICS & DRUG DELIVERY 1 NEURSURGERY NAVIGATION 2 VISUALASE LASER THERAPY & ACCESS 3 CLEARPOINT NAVIGATION IS COMPATIBLE WITH MAJOR DIAGNOSTIC AND INTRAOPERATIVE MRI AND CT SC
Slide 15: Hospital customer sites
Banner Health Tucson Baptist Memorial Hospital-Memphis Barnes-Jewish Hospital Barrow Neurological Institute/St. Joseph's Hospital Benioff Children's Hospital Beth Israel Deaconess Boston Children's Hospital Brigham & Women's Hospital Brown University / Rhode Island Hospital Carilion Clinic Children'
Slide 16: Building the Business: Development, Quality and Supply Infrastructure
Building the Business Funded. Foundation. © 2025 CLEARPOINT NEURO We have invested in the Development, Quality and Supply infrastructure to build confidence for both Hospitals and BioPharma partners We are not a start-up company but an experienced and sophisticated medical device extension for any c
Slide 17: Building the Business: Key Metrics and Revenue Growth
Building the Business Funded. Foundation. © 2025 CLEARPOINT NEURO Key Products: Marked Platforms EMPLOYEES 100+ 2024 REVENUE $31.4m(A) CASH & CASH EQUIVALENTS $12.1 m(B,C) HEADQUARTERS Solana Beach, CA GROSS MARGIN 61%(B,E) MANUFACTURING Carlsbad, CA For the year ended December 31, 2024 Unaudited, a
Slide 18: Executive Leadership Team
Building the Business Funded. Foundation. © 2025 CLEARPOINT NEURO Joe Burnett President & Chief Executive Officer Danilo D’Alessandro Chief Financial Officer Jeremy Stigall Chief Business Officer Mazin Sabra Chief Operating Officer Ellisa Cholapranee General Counsel Megan Faulkenberry Vice President
Slide 19: In 2025 Our Journey Enters the Next Chapter
In 2025 Our Journey Enters the NEXT CHAPTER Our Company © 2025 CLEARPOINT NEURO Discovery. Design. Neurosurgeon Led Ideation Unique MRI Navigation Initial FDA Clearance and Product Revenue Accumulation of Clinical Trial Experience Using SmartFlow® Maestro A.I. Software Development Initial IP Generat
Slide 20: We are Pointing the Way for a Cell and Gene Therapy Future
We are Pointing the Way for a Cell and Gene Therapy Future: Fast. Forward. Fast. Forward. Our Commitment to Hospitals & BioPharma Partners is to help prepare for tens-of-thousands of anticipated new patients who will be seeking these restorative therapies Extend Our Lead in Neuro Drug Delivery by le
Slide 21: Our 4 Pillar Growth Strategy Continues 2025-2027
3 LASER THERAPY & ACCESS 2 NEUROSURGERY NAVIGATION BIOLOGICS & DRUG DELIVERY 2027 2025 COMPLETE PRISM LASER & VELOCITY DRILL LAUNCHES 4 GLOBAL SCALE ACTIVATE 150 CENTERS & GROW REVENUE FASTER THAN OPEX © 2025 CLEARPOINT NEURO 1 ADD PRE-CLINICAL GLP SERVICES & NEW ROUTES OF ADMINISTRATION EXPAND INTO
Slide 22: Growth Strategy Milestones 2025-2027
3 LASER THERAPY & ACCESS 2 NEUROSURGERY NAVIGATION BIOLOGICS & DRUG DELIVERY 2027 2025 Add 1.5 Tesla PRISM for full market access Add Ablation Coverage & Predictive Thermal Modeling Launch MRI Conditional Power Drill to reduce procedure time 4 GLOBAL SCALE Expand Global Footprint to 150+ Centers Per
Slide 23: GLP Services & New Routes of Administration
GLP Services & New Routes of Administration Fast. Forward. Market Growth Drivers: Improved BioPharma Funding Environment Additional cell and gene therapies entering the ‘funnel’ Partner progression into larger spend GLP studies and clinical trials Successful implementation of FDA ‘Expedited Review’
Slide 24: Neuro Navigation, Therapy and Access Product Growth
Market Growth Drivers: Asleep DBS FDA Clearance and Patient Awareness New DBS Indications including Epilepsy, OCD, Depression, BCI Increased hospital throughput of laser therapy compared to open surgery Improved laser insurance decisions and awareness Additional global approvals in EU and APAC Marke
Slide 25: In 2025 Our Journey Enters the Next Chapter
In 2025 Our Journey Enters the NEXT CHAPTER Our Company © 2025 CLEARPOINT NEURO Discovery. Design. Neurosurgeon Led Ideation Unique MRI Navigation Initial FDA Clearance and Product Revenue Accumulation of Clinical Trial Experience Using SmartFlow® Maestro A.I. Software Development Initial IP Generat
Slide 26: The FDA & Global Notified Bodies Recognize the Urgency
© 2025 CLEARPOINT NEURO Partners have programs selected for expediated review - the FDA recognizes the urgency The FDA & Global Notified Bodies Recognize the Urgency Essential. Everywhere. 7 Partner has received FDA approval for a neuro gene therapy that is co-labeled with ClearPoint 1
Slide 27: 60+ Active BioPharma Programs across 20+ Indications
ClearPoint has 60+ Active BioPharma Programs across 20+ indications including DBS, LiTT Essential. Everywhere. © 2025 CLEARPOINT NEURO BENCHTOP TESTING PRECLINICAL STUDIES Device Compatibility Testing Infusion Pump Testing Custom Device Development Performance Assessment Device Comparisons / Bridgin
Slide 28: Partnerships Enabled by the ClearPoint Ecosystem
Sophisticated Partnerships are Enabled by the ClearPoint Ecosystem of Products & Services Essential. Everywhere. © 2025 CLEARPOINT NEURO ClearPoint May Provide to BioPharma; Assurance of Supply Access to FDA Device Dossier Redundant Global Manufacturing Contracted Commercial Pricing Licenses to Key
Slide 29: ClearPoint is Diversified Across Partners and Indications
More than 30 Million People in the U.S. alone suffer from severe and debilitating neurological disorders; Parkinson’s Disease (1.0m) Essential Tremor (7.0m) Epilepsy (2.9m) Huntington’s Disease (41k) Rare Childhood Genetic Disorders (25k) Dementia and Alzheimer’s Disease (6.9m) Tumor and Glioblastom
Slide 30: ClearPoint Neuro Executive Summary
CLEARPOINT NEURO EXECUTIVE SUMMARY 15+ years building a complete drug delivery ecosystem including navigation solutions, predictive modeling, delivery devices, infusion monitoring software and clinical case support Combination device success, proprietary technology and deep FDA experience provide ou
Slide 31: Sources
Sources © 2025 CLEARPOINT NEURO Sources Alzheimer's Association 2024 Alzheimer's Disease Facts and Figures How Many People in the USA Have Essential Tremor? Deriving a Population Estimate Based on Epidemiological Data - PMC Parkinson's Disease: Challenges, Progress, and Promise | National Institute